



NDA 21-374/S-001

Wyeth Consumer Healthcare
Attention: Barbara Wolfe, Pharm.D.
Associate Director, Regulatory Affairs
5 Giralda Farms
Madison, NJ 07940

Dear Dr. Wolfe:

Please refer to your supplemental new drug application dated August 12, 2003, received August 15, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Advil Cold and Sinus Liquigels (200 mg ibuprofen and 30 mg pseudoephedrine HCl capsules).

This "Changes Being Effected" supplemental new drug application provides revised labeling including new/revised warnings and a revised Statement of Identity.

We completed our review of this supplemental new drug application. It is approved, effective on the date of this letter, for use as recommended in the final printed labeling (FPL) submitted on August 12, 2003.

The Agency is concerned about the need for organ-specific warnings for OTC drug products containing analgesic/antipyretic active ingredients. We will provide guidance on wording and placement of organ-specific warnings in the labeling of drug products containing NSAID's and/or acetaminophen in the future.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Leah Cutter, Ph.D., Regulatory Project Manager, at (301) 827-2248.

Sincerely,

{See appended electronic signature page}

Curtis Rosebraugh, M.D.
Deputy Director
Division of Over-the-Counter Drug Products
Office of Drug Evaluation V
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Curtis Rosebraugh
10/17/03 10:10:18 AM